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Outcomes in Diabetic and Nondiabetic Patients
Treated With Everolimus- or Paclitaxel-Eluting Stents
Results From the SPIRIT IV Clinical Trial (Clinical Evaluation
of the XIENCE V Everolimus Eluting Coronary Stent System)
Dean J. Kereiakes, MD,* Donald E. Cutlip, MD,† Robert J. Applegate, MD,‡ John Wang, MD,§
Manejeh Yaqub, MD, Poornima Sood, MD, MBA, Xiaolu Su, MS, Guoping Su, PHD,
Naim Farhat, MD,¶ Ali Rizvi, MD,# Charles A. Simonton, MD, Krishnankutty Sudhir, MD, PHD,
Gregg W. Stone, MD**
Cincinnati and Elyria, Ohio; Boston, Massachusetts; Winston-Salem, North Carolina; Baltimore, Maryland;
Santa Clara, California; Houston, Texas; and New York, New York
Objectives We compared the safety and efficacy of the XIENCE V (Abbott Vascular, Santa Clara, California) everolimus-
eluting stent (EES) with the TAXUS Express (Boston Scientific, Natick, Massachusetts) paclitaxel-eluting stent
(PES) among the large cohort of randomized diabetic patients enrolled in the SPIRIT IV (Clinical Evaluation of the
XIENCE V Everolimus Eluting Coronary Stent System) trial.
Background Diabetes mellitus remains a significant predictor of adverse clinical outcomes after percutaneous coronary inter-
vention with drug-eluting stents, and the comparative outcomes of different drug-eluting stents in diabetic pa-
tients remains ill-defined.
Methods In the SPIRIT IV trial, 3,687 patients with up to 3 de novo native coronary artery lesions were prospectively random-
ized 2:1 to receive EES or PES. Randomization was stratified by the presence of diabetes and lesion complexity. The
primary end point was the occurrence of target lesion failure (TLF) (cardiac death, target-vessel myocardial infarction,
or ischemia-driven target lesion revascularization) at 1 year. Clinical outcomes were evaluated in randomized diabetic
(n  1,185 [786 EES; 399 PES]) and nondiabetic patients (n  2,498 [1,669 EES; 829 PES]).
Results The EES compared with PES reduced TLF in nondiabetic patients (3.1% vs. 6.7%, p  0.0001), with significant
reductions in myocardial infarction, stent thrombosis, and target lesion revascularization. In contrast, no differ-
ence in TLF (6.4% vs. 6.9%, respectively, p  0.80) or any of its components was present among diabetic pa-
tients, regardless of insulin use. A significant interaction between the presence of diabetes and stent type on TLF
(pinteraction  0.02) was observed.
Conclusions In the SPIRIT IV randomized trial, EES compared with PES provided similar clinical outcomes in diabetic patients and supe-
rior clinical outcomes in nondiabetic patients at 1 year. (SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V Everoli-
mus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions;
NCT00307047) (J Am Coll Cardiol 2010;56:2084–9) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.10.006a
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December 14/21, 2010:2084–9 Everolimus-Eluting Stents in Diabetic Patientsascular risk factors (3). Greater plaque burden and neointimal
roliferation also contribute to increased restenosis after coro-
ary stent deployment (4).
Although drug-eluting stents (DES) reduce angiographic
nd clinical restenosis compared with bare-metal stents in
atients both with and without diabetes (5,6), the presence of
iabetes remains a significant predictor of adverse outcomes in
he DES era (7). Late (2- to 4-year) clinical follow-up from
ultiple randomized trials and clinical registries of DES versus
are-metal stents have demonstrated reduced target lesion
evascularization (TLR) with no appreciable differences in
eath, myocardial infarction (MI), or stent thrombosis with
ES use in diabetic patients (8–10). Although numerous
tudies have demonstrated less in-stent late lumen loss and
educed neointimal hyperplasia after sirolimus-eluting stents
SES) versus paclitaxel-eluting stents (PES) in diabetic pa-
ients, clinical events—including TLR and major adverse
ardiovascular events (MACE)—have been similar between
tent types (11–13). In the SPIRIT III (Clinical Evaluation of
he XIENCE V Everolimus Eluting Coronary Stent System),
o significant differences were observed between PES and
verolimus-eluting stents (EES) for the co-primary end points
f late loss or target vessel failure among 290 randomized
atients with diabetes mellitus, and a significant interaction
as noted between stent type and event-free survival (14).
t has been proposed that the direct effect of paclitaxel
aseline Demographic and Angiographic Characteristics of DiabetiTable 1 Baseline Demographic and Angiographic Characteristic
Diabetic Patients
EES
n  786
M  1,026
PES
n  399
M  523
Demographic features
Age (yrs) 63.06 10.05 63.48 10.1
Male 64.4% (506/786) 62.2% (248/3
Hypertension 86.2% (676/784) 87.7% (350/3
Hypercholesterolemia 84.4% (657/778) 80.6% (320/3
Current smoker 19.1% (147/769) 17.4% (67/38
Prior MI 22.9% (173/756) 18.0% (70/38
Unstable angina 29.5% (228/772) 28.4% (110/3
Target lesion characteristics
Coronary artery location
Left anterior descending 38.9% (399/1,026) 40.2% (210/5
Left circumflex 26.7% (274/1,026) 27.0% (141/5
Right 34.4% (353/1,026) 32.9% (172/5
ACC/AHA lesion class
A 8.4% (86/1,018) 14.3% (74/51
B1 40.8% (415/1,018) 39.3% (204/5
B2 30.4% (309/1,018) 27.6% (143/5
C 20.4% (208/1,018) 18.9% (98/51
B1/B2/C 91.6% (932/1,018) 85.7% (445/5
Reference vessel diameter, mm 2.72 0.48 2.76 0.49
Minimal luminal diameter, mm 0.73 0.37 0.76 0.38
Diameter stenosis, % 72.4 12.2 71.7 12.3
Lesion length, mm 15.1 6.7 14.6 6.8is the number of patients; M is the number of lesions.
ACC/AHA  American College of Cardiology/American Heart Association; EES  everolimus-eluting stn microtubule function inhibits
nsulin-regulated signal transduc-
ion pathways, thus mitigating the
eleterious effect of diabetes on
ncreasing neointimal hyperplasia
15). However, prior studies were
ot adequately powered to evalu-
te differences in clinical safety or
fficacy between DES types.
The SPIRIT IV (Clinical Eval-
ation of the XIENCE V Everoli-
us Eluting Coronary Stent Sys-
em) trial was a large prospective
andomized trial comparing EES
nd PES in subjects with de novo
ative coronary atherosclerosis,
ith randomization stratified by
he presence of diabetes mellitus
16,17). This pre-specified dia-
etic cohort analysis involves 1,185
iabetic patients enrolled into the
PIRIT IV trial.
ethods
he SPIRIT IV trial was a prospective, multicenter,
ingle-blind, active-controlled trial in which 3,687 pa-
Nondiabetic CohortsDiabetic and Nondiabetic Cohorts
Nondiabetic Patients
p Value
EES
n  1,669
M  2,112
PES
n  829
M  1,061 p Value
0.50 63.33 10.74 63.28 10.28 0.90
0.48 69.3% (1,156/1,669) 70.6% (585/829) 0.52
0.53 73.2% (1,221/1,667) 70.5% (584/828) 0.15
0.10 72.1% (1,176/1,630) 73.0% (596/816) 0.67
0.52 23.2% (380/1,639) 24.7% (201/814) 0.42
0.07 20.3% (330/1,629) 20.8% (169/813) 0.79
0.73 26.9% (441/1,641) 29.2% (237/813) 0.25
0.66 41.2% (871/2,112) 39.6% (420/1,061) 0.38
0.95 22.9% (484/2,112) 24.7% (262/1,061) 0.27
0.57 35.8% (757/2,112) 35.7% (379/1,061) 0.97
0.0006 12.5% (261/2,096) 14.2% (150/1,053) 0.16
0.62 39.1% (820/2,096) 40.5% (426/1,053) 0.49
0.26 28.8% (603/2,096) 28.1% (296/1,053) 0.71
0.50 19.7% (412/2,096) 17.2% (181/1,053) 0.10
0.0006 87.5% (1,835/2,096) 85.8% (903/1,053) 0.16
0.21 2.76 0.47 2.75 0.45 0.79
0.15 0.75 0.38 0.75 0.39 0.91
0.24 72.2 12.8 72.1 13.0 0.90
0.21 14.7 6.6 14.5 6.6 0.57
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
ID-TLR  ischemia-driven
target lesion
revascularization
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TLF  target lesion failure
TLR  target lesion
revascularizationc ands of
5
99)
99)
97)
5)
8)
88)
23)
23)
23)
9)
19)
19)
9)
19)ent(s); MI  myocardial infarction; PES  paclitaxel-eluting stent(s).
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Everolimus-Eluting Stents in Diabetic Patients December 14/21, 2010:2084–9ients with coronary artery disease undergoing PCI were
andomized 2:1 to EES (XIENCE V, Abbott Vascular,
anta Clara, California) or PES (TAXUS Express2,
oston Scientific, Natick, Massachusetts) (16). The trial
nrolled 1,185 patients with diabetes, and stratification
ccording to the presence of diabetes occurred before
andomization to ensure that the 2:1 (EES vs. PES)
andomization ratio was preserved and that measured and
nmeasured confounders were likely to be balanced in the
iabetic subgroup (17). Routine follow-up angiography
as not performed in the SPIRIT IV trial, unlike the
PIRIT III trial (14).
nclusion and exclusion criteria. The SPIRIT IV trial design
as been described previously (16). Angiographic inclusion and
xclusion criteria are provided in the Online Appendix.
After confirmation of angiographic eligibility, telephone
andomization was performed, stratified by the presence of
iabetes, complex lesions, and study site.
evice description. The XIENCE V EES has been de-
cribed previously (16). In the SPIRIT IV trial, EES were
vailable in diameters of 2.5 to 4.0 mm and lengths of 8, 18,
nd 28 mm. The full range of commercially available PES
as available in diameters of 2.5 to 3.5 mm and lengths of
, 12, 16, 18, 22, 28, and 32 mm.
rocedure and follow-up. Balloon pre-dilation of the
arget lesion was mandatory. Additional stents used for
ailout purposes were required to be from the same
reatment arm. Aspirin 300 mg was administered
efore the procedure, and oral clopidogrel load 300 mg
as recommended before the procedure and required
rocedural Results and Angiographic Outcomes in Diabetic and NoTable 2 Procedural Results and Angiographic Outcomes in Diab
Diabetic Patien
EES
n  786
M  1,026
PES
n  3
M  5
Procedural variables
Stents/patient, n 1.5 0.7 1.5
Stents/lesion, n 1.2 0.4 1.2
Maximum stent diameter/lesion (mm) 2.98 0.39 2.99
Maximum stent diameter/RVD ratio 1.11 0.15 1.10
Total stent length/lesion 22.5 9.0 21.0
Total stent/lesion length ratio 1.61 0.56 1.53
Maximum pressure (atm) 15.2 3.1 15.7
Glycoprotein IIb/IIIa inhibitors used 19.6% (154/786) 17.0% (68
Post-procedural angiographic results
Minimal luminal diameter, mm
In-stent 2.67 0.44 2.69
In-segment 2.33 0.46 2.35
Diameter stenosis, %
In-stent 1.2 8.2 1.4
In-segment 14.1 7.0 13.9
Acute gain, mm
In-stent 1.93 0.46 1.92
In-segment 1.59 0.47 1.59is the number of patients; M is the number of lesions.
RVD  reference vessel diameter; other abbreviations as in Table 1.ithin 1 h after stent deployment. Aspirin 80 mg daily
as administered indefinitely, and clopidogrel 75 mg
aily was prescribed for 12 months. Clinical follow-up
as scheduled at 30, 180, 270, and 365 days and then
early through 5 years. Follow-up angiography was not
pecified by protocol.
linical end points. End point definitions have been
escribed previously (16 –18). The primary end point was
arget lesion failure (TLF) at 1 year (composite of cardiac
eath, target-vessel MI, or ischemia-driven target lesion
evascularization [ID-TLR]). The major secondary end
oints were ID-TLR and the composite occurrence of
ardiac death or target-vessel MI. Additional pre-
pecified secondary end points included MACE (com-
osite of cardiac death, MI, or ID-TLR), target vessel
ailure (cardiac death, MI, or ischemia-driven target
essel revascularization) as well as its individual compo-
ents, and stent thrombosis as defined per protocol (16)
nd by the Academic Research Consortium criteria (18).
tatistical methods. Subgroup classifications according
o presence or absence of diabetes and type of diabetic
reatment (insulin- vs. noninsulin-requiring) were pre-
pecified (16). All data are presented on the basis of the
ntent-to-treat principle. Selected baseline characteristics
nd 1-year clinical outcomes were compared between
reatment groups and various diabetes strata, and adjust-
ents were not made for multiple comparisons. Categor-
cal variables were compared by Fisher exact test. Con-
inuous variables are presented as mean  1 SD and were
ompared by t test.
etic Cohortsand Nondiabetic Cohorts
Nondiabetic Patients
p Value
EES
n  1,669
M  2,112
PES
n  829
M  1,061 p Value
0.73 1.5 0.8 1.4 0.8 0.40
0.36 1.17 0.44 1.13 0.38 0.02
0.35 3.02 0.39 3.02 0.37 0.83
0.59 1.11 0.14 1.11 0.14 0.87
0.003 22.3 8.8 20.9 8.5 0.0001
0.02 1.66 0.77 1.56 0.68 0.0001
0.005 15.3 2.9 15.8 2.9 0.0001
0.31 18.8% (313/1,669) 21.2% (176/829) 0.15
0.41 2.71 0.43 2.72 0.42 0.28
0.29 2.37 0.45 2.36 0.45 0.74
0.61 1.4 7.4 0.8 8.3 0.09
0.60 14.1 6.9 14.5 7.5 0.15
0.76 1.95 0.50 1.97 0.48 0.35
0.99 1.62 0.50 1.61 0.51 0.73ndiabetic
ts
99
23
0.8
0.5
0.39
0.15
9.8
0.63
3.0
/399)
0.44
0.47
7.9
7.4
0.47
0.49
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December 14/21, 2010:2084–9 Everolimus-Eluting Stents in Diabetic Patientsesults
aseline characteristics and procedural outcomes. Base-
ine clinical and angiographic characteristics stratified by the
resence of diabetes and randomly assigned stent type are
hown in Table 1. Procedural results and angiographic
utcomes are shown in Table 2. Due to the limitation in
tent lengths available for EES (3 lengths) versus PES (7
engths), stent length/lesion and stent-length/lesion-length
atio were slightly greater with EES than PES.
linical outcomes at 1 year. Among nondiabetic patients,
ES compared with PES reduced the primary end point of
LF by 54% (3.1% vs. 6.7%, p  0.0001) and MACE by
2% (3.2% vs. 6.7%, p  0.0001). The EES resulted in
ignificantly lower rates of the major secondary end points
f ID-TLR and the composite occurrence of cardiac death
r target-vessel MI (Table 3). Furthermore, EES resulted in
educed rates of target-vessel MI (both Q-wave and non–
-wave) as well as stent thrombosis (by both protocol and
cademic Research Consortium definitions).
In contrast, among patients with diabetes, clinical out-
omes to 1 year were not significantly different between
andomly assigned stent types for both TLF and MACE.
or were significant differences in the components of the
omposite clinical end points or the rates of stent throm-
osis observed between stent types. Clinical event rates to 1
ear were not significantly different between randomly
linical Outcomes at 1 Year According to Presence of DiabetesTable 3 Clinical Outcomes at 1 Year According to Presence of
Diabetic Patients
EES
(n  786)
PES
(n  399)
Target lesion failure 6.4% (49/761) 6.9% (26/379)
Major adverse cardiac events 6.4% (49/761) 7.1% (27/379)
Target vessel failure 8.4% (64/761) 8.4% (32/379)
Death or MI 4.1% (31/761) 4.5% (17/379)
Cardiac death or MI* 3.4% (26/761) 4.0% (15/379)
Cardiac death or target vessel MI 3.4% (26/761) 3.7% (14/379)
MI, all* 2.6% (20/761) 3.7% (14/379)
Q-wave 0.3% (2/761) 0.3% (1/379)
Non–Q-wave 2.4% (18/761) 3.4% (13/379)
MI, target vessel 2.6% (20/761) 3.4% (13/379)
Q-wave 0.3% (2/761) 0.3% (1/379)
Non–Q-wave 2.4% (18/761) 3.2% (12/379)
Death, all 1.6% (12/761) 0.8% (3/379)
Cardiac death 0.9% (7/761) 0.3% (1/379)
Target lesion 4.2% (32/761) 4.7% (18/379)
Target vessel 3.9% (30/761) 2.9% (11/379)
Stent thrombosis
Protocol definition 0.53% (4/749) 1.33% (5/376)
Acute (24 h) 0.38% (3/780) 0.25% (1/396)
Subacute (24 h to 30 days) 0.00% (0/780) 0.51% (2/394)
Late (30 days) 0.13% (1/749) 0.53% (2/376)
ARC definite or probable 0.80% (6/751) 1.33% (5/376)Ischemia-driven events.
ARC  Academic Research Consortium; other abbreviations as in Tables 1 and 2.ssigned stent treatments in both insulin-requiring and
oninsulin-requiring diabetic patients (Table 4).
Logistic regression analysis demonstrated a significant
nteraction between diabetes and stent type on the primary
nd point of TLF (p  0.02) (Fig. 1). No interaction
etween diabetes type (insulin-requiring or not) and stent
ype with TLF was observed (p  0.56) (Fig. 2).
iscussion
he major findings from this pre-specified SPIRIT IV
iabetic cohort analysis are: 1) even though EES compared
ith PES markedly reduced adverse clinical outcomes at 1
ear in nondiabetic patients, results in diabetic patients were
omparable, regardless of stent type; and 2) no differences in
-year clinical outcomes after EES versus PES were ob-
erved in patients with diabetes, regardless of insulin re-
uirement.
The SPIRIT IV trial confirms and extends the observa-
ion made in the SPIRIT III trial of a significant interaction
etween randomized stent type (EES vs. PES) and the
resence of diabetes on the primary composite safety-plus-
fficacy clinical end point. However, explanation(s) for the
pparent attenuation in the relative benefit afforded by EES
ersus PES among diabetic patients is unknown.
Of note, TLF to 1 year after PES was similar among
ondiabetic patients (6.7%), noninsulin-requiring diabetic pa-
ients (6.8%), and insulin-requiring diabetic patients (7.0%).
etes
Nondiabetic Patients
p Value
EES
(n  1,669)
PES
(n  829) p Value
0.80 3.1% (52/1,652) 6.7% (55/815) 0.0001
0.71 3.2% (53/1,652) 6.7% (55/815) 0.0001
1.00 4.3% (71/1,652) 7.6% (62/815) 0.0009
0.76 2.2% (37/1,652) 3.9% (32/815) 0.02
0.62 1.7% (28/1,652) 2.9% (24/815) 0.05
0.86 1.6% (27/1,652) 2.9% (24/815) 0.04
0.36 1.5% (25/1,652) 2.8% (23/815) 0.03
1.00 0.1% (1/1,652) 0.5% (4/815) 0.04
0.33 1.5% (24/1,652) 2.5% (20/815) 0.10
0.46 1.5% (24/1,652) 2.7% (22/815) 0.04
1.00 0.1% (1/1,652) 0.5% (4/815) 0.04
0.44 1.4% (23/1,652) 2.3% (19/815) 0.10
0.41 0.8% (13/1,652) 1.5% (12/815) 0.13
0.28 0.2% (3/1,652) 0.5% (4/815) 0.23
0.65 1.8% (29/1,652) 4.5% (37/815) 0.0001
0.40 1.6% (26/1,652) 3.2% (26/815) 0.01
0.17 0.00% (0/1,637) 0.62% (5/804) 0.004
1.00 0.00% (0/1,668) 0.48% (4/828) 0.01
0.11 0.00% (0/1,668) 0.00% (0/826) NA
0.26 0.00% (0/1,637) 0.25% (2/804) 0.11
0.52 0.06% (1/1,637) 1.00% (8/804) 0.0009Diab
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Everolimus-Eluting Stents in Diabetic Patients December 14/21, 2010:2084–9onversely, TLF after EES treatment occurred in 3.1% of
ondiabetic patients, 5.9% of noninsulin-requiring diabetic
atients, and 8.0% of insulin-requiring diabetic patients. Sim-
lar relative differences were observed for other clinical end
oints when stratified by stent type as well as the presence and
everity of diabetes. Thus, adverse events in diabetic (vs.
ondiabetic) patients were increased after PCI with EES. In
ontrast, PES seems to mitigate both the presence and severity
f diabetes as a risk factor for adverse outcomes. This obser-
ation seems counter to the findings of the SPIRIT V diabetic
linical Outcomes at 1 Year in Noninsulin- and Insulin-Dependent DTable 4 Clinical Outcomes at 1 Year in Noninsulin- and Insulin-
Noninsulin-Dependent Diabetic
EES
(n  577)
PES
(n  280)
Target lesion failure 5.9% (33/562) 6.8% (18/264
Major adverse cardiac events 5.9% (33/562) 6.8% (18/264
Target vessel failure 7.1% (40/562) 8.0% (21/264
MI, all* 2.5% (14/562) 3.0% (8/264)
Q-wave 0.2% (1/562) 0.4% (1/264)
Non–Q-wave 2.3% (13/562) 2.7% (7/264)
MI, target-vessel 2.5% (14/562) 3.0% (8/264)
Q-wave 0.2% (1/562) 0.4% (1/264)
Non–Q-wave 2.3% (13/562) 2.7% (7/264)
Target lesion revascularization* 3.6% (20/562) 4.9% (13/264
Stent thrombosis
Protocol definition 0.54% (3/554) 1.53% (4/262)
Acute (24 h) 0.35% (2/573) 0.36% (1/278)
Subacute (24 h to 30 days) 0.00% (0/573) 0.36% (1/276)
Late (30 days) 0.18% (1/554) 0.76% (2/262)
ARC definite or probable 0.72% (4/555) 1.53% (4/262)
Ischemia-driven events.
Abbreviations as in Tables 1, 2, and 3.
Figure 1 Target Lesion Failure Through 1 Year for
Patients According to Presence of Diabetes Mellitus
Target lesion failure was similar among diabetic patients treated with an
everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) and was mark-
edly reduced by EES in the nondiabetic cohort. A significant interaction
between stent type and diabetes was identified. CI  confidence interval;
RR  risk ratio.andomized trial, which compared the XIENCE V (Abbott
ascular) EES with the TAXUS Liberté (Boston Scientific)
ES (19). Important differences between these trials exist. The
PIRIT V diabetic trial had an angiographic primary end point
in-stent late loss at 270 days) with protocol-mandated angiog-
aphy and follow-up. Although EES (vs. PES) produced
n-stent late loss, no statistically significant differences in
n-segment late loss or in binary angiographic restenosis were
bserved, and the study was grossly underpowered for assess-
ent of clinical outcomes. Thus, although the direct effects of
ic Patientsndent Diabetic Patients
nts Diabetic Patients Requiring Insulin
p Value
EES
(n  209)
PES
(n  119) p Value
0.64 8.0% (16/199) 7.0% (8/115) 0.83
0.64 8.0% (16/199) 7.8% (9/115) 1.00
0.67 12.1% (24/199) 9.6% (11/115) 0.58
0.65 3.0% (6/199) 5.2% (6/115) 0.37
0.54 0.5% (1/199) 0.0% (0/115) 1.00
0.81 2.5% (5/199) 5.2% (6/115) 0.22
0.65 3.0% (6/199) 4.3% (5/115) 0.54
0.54 0.5% (1/199) 0.0% (0/115) 1.00
0.81 2.5% (5/199) 4.3% (5/115) 0.51
0.35 6.0% (12/199) 4.3% (5/115) 0.61
0.22 0.51% (1/195) 0.88% (1/114) 1.00
1.00 0.48% (1/207) 0.00% (0/118) 1.00
0.33 0.00% (0/207) 0.85% (1/118) 0.36
0.24 0.00% (0/195) 0.00% (0/114) NA
0.28 1.02% (2/196) 0.88% (1/114) 1.00
Figure 2 Target Lesion Failure Through 1 Year Among
Diabetic Patients Requiring and Not Requiring Insulin
Target lesion failure was similar among diabetic patients treated with EES or
PES, regardless of the requirement for insulin therapy. No interaction between
stent type and requirement for insulin therapy was identified in the diabetic
cohort. Abbreviations as in Figure 1.iabetDepe
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December 14/21, 2010:2084–9 Everolimus-Eluting Stents in Diabetic Patientsaclitaxel in inhibiting insulin-regulated intracellular signal
ransduction pathways provide theoretic appeal for paclitaxel
lution by DES in patients with diabetes (15), everolimus
lution provided comparable clinical benefit among diabetic
atients with reference vessel diameters2.5 mm enrolled into
he current study.
The lower 1-year rates of stent thrombosis after EES (vs. PES)
n the SPIRIT IV and COMPARE (Second-generation
verolimus-eluting and paclitaxel-eluting stents in real-life prac-
ice) randomized trials (17,20) have prompted speculation regard-
ng potential “thromboresistant” properties of the EES biostable
uorocopolymer (21,22). In this regard, an even larger diabetic
ohort than was enrolled in the SPIRIT IV trial would be required
o determine whether the nonsignificant trend toward fewer stent
hrombosis events observed in diabetic patients treated with EES
vs. PES) represents a real difference or is due to chance.
Finally, despite the stratification of randomization for the
resence of diabetes mellitus, specific covariate imbalance
as observed in baseline angiographic as well as procedural
ariables among diabetic subjects stratified by stent type.
iabetic subjects treated with PES had a higher prevalence
f American College of Cardiology/American Heart Asso-
iation Type A and a lower prevalence of Type B1/B2/C
ngiographic lesion morphology than those who received
reatment with EES. Furthermore, total stent length/lesion
nd total stent-length/lesion-length ratio were less in PES-
reated diabetic and nondiabetic subjects, whereas the max-
mum stent deployment pressure was increased. Each of the
nequities observed, particularly more complex target lesion
orphology and longer stent length, would be expected to
isadvantage the EES-treated cohort.
onclusions
lthough EES (vs. PES) reduced the study primary end point
f TLF as well as the major secondary end points of cardiac
eath or target-vessel MI and ID-TLR in patients without
iabetes mellitus, no significant differences in outcomes were
bserved between DES types among diabetic patients, regard-
ess of insulin requirement. These findings suggest the need for
urther studies to elucidate the mechanistic pathways underly-
ng the poor prognosis of patients with diabetes mellitus, with
focus toward development of novel drugs and stents to
mprove outcomes in this high-risk patient cohort.
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